Kandukuri Shivani R, Rao Jianyu
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, California, USA.
Curr Opin Obstet Gynecol. 2015 Feb;27(1):48-52. doi: 10.1097/GCO.0000000000000135.
Recent progress in the understanding of the molecular events in ovarian cancer has prompted the need for a revised International Federation of Gynecology and Obstetrics (FIGO) staging system that may provide more accurate prognostic information and more specific guidance on personalized management of ovarian cancer than the older staging system that was last revised in 1988. In particular, it is now realized that cancer of ovary, fallopian tube, and peritoneum share similar molecular characteristics and should be considered collectively. With that, a new FIGO staging guideline for cancer of the ovary, fallopian tube, and peritoneum was approved by the FIGO executive board in October 2012 and published in the International Journal of Gynecology Obstetrics [2014; 124:1-5]. Several revisions have been made to the older staging system that needs to be elucidated so that accurate and appropriate patient care may be practiced.
The standardization of the staging system allows for a smoother transition of patient care between institutions and overall better communication and continuity of management.
Our article briefly reviews and discusses the differences between the new and the old staging system of 1988.
对卵巢癌分子事件认识的最新进展促使国际妇产科联盟（FIGO）修订分期系统，相较于1988年最后修订的旧分期系统，新系统可能为卵巢癌的个性化管理提供更准确的预后信息和更具体的指导。特别是，现在已经认识到卵巢癌、输卵管癌和腹膜癌具有相似的分子特征，应一并考虑。据此，FIGO执行委员会于2012年10月批准了一项针对卵巢癌、输卵管癌和腹膜癌的新FIGO分期指南，并发表于《国际妇产科杂志》[2014; 124:1 - 5]。旧分期系统已进行了多项修订，需要予以阐明，以便实施准确且恰当的患者护理。
分期系统的标准化有助于患者护理在不同机构间更平稳地过渡，总体上改善管理的沟通与连续性。
我们的文章简要回顾并讨论了新分期系统与1988年旧分期系统之间的差异。
